Popular on Rezul


Similar on Rezul

California: Governor Newsom announces affordable CalRx® insulin, $11 a pen, will soon be available for purchase

Rezul News/10717827
News

Oct 16, 2025

Governor Newsom announces affordable CalRx® insulin, $11 a pen, will soon be available for purchase

What you need to know: Governor Newsom announced that California's CalRx® Insulin Glargine in pen form will be available to consumers for a suggested retail price of not more than $55 per five-pack of pens (average cost of $11 per pen) beginning January 1, 2026, reducing barriers to accessing this essential diabetes medication.

SACRAMENTO – As the first and only state contracting for its own affordable insulin, Governor Gavin Newsom today announced that CalRx® biosimilar insulin glargine pens will be available to consumers in California beginning January 1, 2026. This launch marks a significant step in the state's ongoing effort to lower prescription drug prices and improve medication access statewide.
Through an agreement secured by Civica Rx — a nonprofit generic drug manufacturer — with Biocon Biologics, Californians will have access to an interchangeable biosimilar insulin glargine pen offered under the CalRx brand and pricing.

"California didn't wait for the pharmaceutical industry to do the right thing — we took matters into our own hands. By beginning the process to manufacture our own insulin and pricing it at a maximum cost of $11 a pen in a five-pack, California and Civica are showing the nation what it looks like to put people over profits. No Californian should ever have to ration insulin or go into debt to stay alive — and I won't stop until health care costs are crushed for everyone."

Governor Gavin Newsom

Insulin glargine is a long-acting insulin analog used in the management of diabetes. The CalRx insulin glargine pens are interchangeable with Lantus®, ensuring seamless substitution for patients, and will be available to California pharmacies for $45 and to consumers at a suggested retail price of no more than $55 per five-pack of 3 mL pens—a substantial reduction from current retail market prices.

"We are grateful for the support of the state of California for our effort to bring affordable insulin to all Americans," said Ned McCoy, President and CEO of Civica.  "The state shares our vision to ensure a sustainable, quality supply of affordable, essential medicines for people who need them."

"Today's action marks a significant milestone in California's ongoing efforts to reduce prescription drug costs," said California Health and Human Services Agency Secretary Kim Johnson. "Lowering the cost of insulin moves us closer to a California where no one is forced to choose between their health and their financial stability."

The insulin glargine pen agreement with Biocon Biologics complements Civica Rx's broader insulin development strategy. Civica Rx continues its ongoing efforts to independently produce interchangeable biosimilar versions of insulin glargine and rapid-acting insulin under the CalRx label, further solidifying a reliable and affordable insulin supply for Californians.

"California is taking action to tackle the insulin affordability crisis," said Elizabeth Landsberg, Director of the Department of Health Care Access and Information (HCAI). "We're committed to transparent pricing, eliminating hidden costs, and ensuring equitable medication access for uninsured, underinsured, and vulnerable residents across our state."

More on Rezul News
"In a moment where inflation is spiking everyday prices for Californians and our health care system is under attack in the form of Medicaid cuts from H.R. 1, a lower cost insulin will bring much needed relief both to California pocketbooks and our state budget," said member Chris Noble, Health Access California's Organizing Director and member of the CalRx Insulin Patient Advisory Council. "California consumers need relief now, so as a person dependent on insulin to live and a health care advocate, I'm relieved to see CalRx moving quickly to lower insulin costs for the people of California while continuing to pursue other needed prescription drug cost solutions."

"California's continued leadership in tackling insulin's broken market is a promising step forward," said Allison Hardt, T1 International's Community Development Director and member of the CalRx Advisory Council. "We celebrate progress that puts patients first and secures insulin at a stable, transparent price while encouraging bold next steps toward true public manufacturing—for people, not for profit."

CalRx initiative

The launch of CalRx-branded insulin is part of a broader strategy of the Governor's first executive order in 2019 to lower prescription drug costs and ensure fair and transparent pricing is accessible to all Californians. To date, no other state has taken action to procure its own affordable medication available for purchase to the public to compete with market-priced products.

Today's announcement builds on the successes of the CalRx Naloxone Access Initiative, which has successfully driven down the market price of naloxone, saving consumers money and helping the state purchase more of this life-saving medication to reverse opioid overdoses. The CalRx program continues to identify opportunities to make drugs more affordable and accessible in California.

Leading the way on affordable health care

Governor Newsom recently signed significant legislation advancing health care affordability by lowering the cost of prescription drugs, including:
  • SB 40, capping consumer cost-sharing for insulin at $35 for a month-long supply.
  • SB 41, reducing prescription drug prices by regulating the practices of pharmacy benefit managers (PBMs), which negotiate prices between drug manufacturers, health care insurance providers, and pharmacies.

Since his first executive order in 2019, Governor Newsom has prioritized making health care more affordable to ensure that families do not have to pick between purchasing medications or having food on the table.

More on Rezul News
For more information on CalRx insulin, visit CalRx Biosimilar Insulin Initiative.

Health care, Press releases, Recent news

https://www.addtoany.com/add_to/facebook?linkur..." rel="nofollow external noopener">https://www.addtoany.com/add_to/x?linkurl=https...">https://www.addtoany.com/add_to/email?linkurl=h...">https://www.addtoany.com/add_to/copy_link?linku...">Recent news

Federal reductions to critical services threaten public safety as flood season gets underway in California

Oct 15, 2025

News What you need to know: As California experiences its first storms of the season, bringing heavy rain, snow, and mudslide concerns to the state, federal reductions in critical forecasting services under the Trump Administration are threatening public safety and...

California steps up to help military, veteran families while the federal government is AWOL

Oct 15, 2025

News What you need to know: California has taken recent steps to help military and veteran families, even as the federal government leaves them behind. SACRAMENTO – As California honors the 250th anniversary of the Armed Forces, the state has taken a number of steps...

YIMBYs rejoice! Leaders celebrate Governor Newsom's landmark actions this year to boost housing and affordability

Oct 15, 2025

News What you need to know: 2025 was the year of abundance, with Governor Newsom taking unprecedented action to reform housing laws, boosting production and affordability. SACRAMENTO – Leaders throughout the state are celebrating Governor Gavin Newsom's unprecedented...

Filed Under: Government, State
Show All News | Report Violation

0 Comments

Latest on Rezul News